In February 2024, the FDA granted accelerated approval to lifileucel, a TIL-derived autologous T-cell therapy, for unresectable or metastatic melanoma previously treated with a PD-1 inhibitor and, if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor. Here, BRAF is linked to metastatic melanoma.